Monaco Alessandro, Casteig Blanco Amaia, Cobain Mark, Costa Elisio, Guldemond Nick, Hancock Christine, Onder Graziano, Pecorelli Sergio, Silva Mitchell, Tournoy Jos, Trevisan Caterina, Votta Mariano, Yfantopoulos John, Yghemonos Stecy, Clay Vincent, Mondello Malvestiti Franco, De Schaetzen Karine, Sykara Georgia, Donde Shaantanu
HEC, Rue de la Libération 1, 78350, Paris, Jouy-en-Josas, France.
Grupo OAT Therapeutic Adherence Observatory, Observatorio de La Salud S.L, Madrid, Spain.
Aging Clin Exp Res. 2021 Oct;33(10):2899-2907. doi: 10.1007/s40520-021-01922-y. Epub 2021 Jul 28.
Policies to combat the COVID-19 pandemic have disrupted the screening, diagnosis, treatment, and monitoring of noncommunicable (NCD) patients while affecting NCD prevention and risk factor control.
To discuss how the first wave of the COVID-19 pandemic affected the health management of NCD patients, identify which aspects should be carried forward into future NCD management, and propose collaborative efforts among public-private institutions to effectively shape NCD care models.
The NCD Partnership, a collaboration between Upjohn and the European Innovation Partnership on Active and Healthy Ageing, held a virtual Advisory Board in July 2020 with multiple stakeholders; healthcare professionals (HCPs), policymakers, researchers, patient and informal carer advocacy groups, patient empowerment organizations, and industry experts.
The Advisory Board identified barriers to NCD care during the COVID-19 pandemic in four areas: lack of NCD management guidelines; disruption to integrated care and shift from hospital-based NCD care to more community and primary level care; infodemics and a lack of reliable health information for patients and HCPs on how to manage NCDs; lack of availability, training, standardization, and regulation of digital health tools.
Multistakeholder partnerships can promote swift changes to NCD prevention and patient care. Intra- and inter-communication between all stakeholders should be facilitated involving all players in the development of clinical guidelines and digital health tools, health and social care restructuring, and patient support in the short-, medium- and long-term future. A comprehensive response to NCDs should be delivered to improve patient outcomes by providing strategic, scientific, and economic support.
抗击新冠疫情的政策扰乱了非传染性疾病(NCD)患者的筛查、诊断、治疗和监测,同时影响了非传染性疾病的预防和危险因素控制。
探讨新冠疫情第一波如何影响非传染性疾病患者的健康管理,确定哪些方面应延续到未来的非传染性疾病管理中,并提出公私机构之间的合作努力,以有效塑造非传染性疾病护理模式。
辉瑞公司与欧洲积极健康老龄化创新伙伴关系合作成立的非传染性疾病伙伴关系于2020年7月与多个利益相关者举行了一次虚拟咨询委员会会议;医疗保健专业人员(HCPs)、政策制定者、研究人员、患者和非正式护理者倡导团体、患者赋权组织和行业专家。
咨询委员会确定了新冠疫情期间非传染性疾病护理在四个方面的障碍:缺乏非传染性疾病管理指南;综合护理中断以及从以医院为基础的非传染性疾病护理转向更多的社区和初级护理;信息疫情以及患者和医疗保健专业人员缺乏关于如何管理非传染性疾病的可靠健康信息;数字健康工具的可用性、培训、标准化和监管不足。
多利益相关者伙伴关系可以促进非传染性疾病预防和患者护理的迅速变革。应促进所有利益相关者之间的内部和相互沟通,让所有参与者参与临床指南和数字健康工具的制定、健康和社会护理结构调整以及短期、中期和长期的患者支持。应提供全面的非传染性疾病应对措施,通过提供战略、科学和经济支持来改善患者结局。